191 related articles for article (PubMed ID: 22172020)
1. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis.
Samouilidou EC; Karpouza AP; Kostopoulos V; Bakirtzi T; Pantelias K; Petras D; Tzanatou-Exarchou H; J Grapsa E
Ren Fail; 2012; 34(2):160-4. PubMed ID: 22172020
[TBL] [Abstract][Full Text] [Related]
2. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
3. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis.
Samouilidou E; Karpouza A; Grapsa E; Tzanatou-Exarchou H
Nephron Clin Pract; 2010; 115(4):c289-94. PubMed ID: 20424480
[TBL] [Abstract][Full Text] [Related]
4. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
5. [Dyslipidemia in patients being treated with peritoneal dialysis].
Zharfbin A
Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
[TBL] [Abstract][Full Text] [Related]
6. Lipid disorders and their relevance to outcomes in chronic kidney disease.
Vaziri ND; Norris K
Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
[TBL] [Abstract][Full Text] [Related]
7. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
10. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
[TBL] [Abstract][Full Text] [Related]
11. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?
Pawlak K; Mysliwiec M; Pawlak D
Life Sci; 2013 Mar; 92(4-5):253-8. PubMed ID: 23295961
[TBL] [Abstract][Full Text] [Related]
12. Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis.
Futatsuyama M; Oiwa T; Komatsu Y
Adv Perit Dial; 2002; 18():192-4. PubMed ID: 12402617
[TBL] [Abstract][Full Text] [Related]
13. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.
Ribeiro S; Faria Mdo S; Silva G; Nascimento H; Rocha-Pereira P; Miranda V; Vieira E; Santos R; Mendonça D; Quintanilha A; Costa E; Belo L; Santos-Silva A
Hemodial Int; 2012 Oct; 16(4):481-90. PubMed ID: 22515595
[TBL] [Abstract][Full Text] [Related]
15. Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.
Papadea P; Kalaitzopoulou E; Skipitari M; Varemmenou A; Papasotiriou M; Papachristou E; Goumenos D; Grune T; Georgiou CD
Redox Biol; 2023 Aug; 64():102762. PubMed ID: 37302344
[TBL] [Abstract][Full Text] [Related]
16. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
Moradi H; Pahl MV; Elahimehr R; Vaziri ND
Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
Gillett MP; Obineche EN; Khan ST; Abdulle AM
Saudi Med J; 2004 Nov; 25(11):1611-6. PubMed ID: 15573187
[TBL] [Abstract][Full Text] [Related]
18. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
19. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
20. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
Samouilidou E; Pantelias K; Petras D; Tsirpanlis G; Bakirtzi J; Chatzivasileiou G; Tzanatos H; Grapsa E
Ther Apher Dial; 2014 Jun; 18(3):279-83. PubMed ID: 24119290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
